Vertex Initiates Phase 2 Medical Trial System for VX-548 for the Procedure of Acute Soreness

Evidence-of-concept analyze of VX-548 in acute ache adhering to bunionectomy surgical procedure open for enrollment –

Second Period 2 analyze of VX-548 in acute soreness next abdominoplasty operation to get started in the coming weeks –

BOSTON, July 19, 2021–(Enterprise WIRE)–Vertex Prescription drugs Integrated (Nasdaq: VRTX) these days announced that it has begun a Phase 2 evidence-of-strategy (POC) research in acute agony adhering to bunionectomy surgical treatment with the selective NaV1.8 inhibitor VX-548 and that it expects to start a next Period 2 study in acute discomfort subsequent abdominoplasty surgical treatment in the coming months.

“Based on the favorable Stage 1 data, we are advancing this plan into Stage 2 with initiation of a dose-ranging POC examine in patients with acute pain following bunionectomy surgical procedures followed rapidly by a second analyze in clients going through abdominoplasty operation. We anticipate to see benefits from the bunionectomy review by Q1 2022,” said Carmen Bozic, M.D., Government Vice President, World wide Medicines Development and Clinical Affairs, and Chief Professional medical Officer at Vertex. “NaV1.8 is a genetically and pharmacologically validated target and we are psyched about the opportunity for VX-548 as a new course of productive suffering remedies without the need of the constraints of existing therapies, like the addictive possible of opioids.”

The Phase 2 scientific tests are randomized, double-blind, placebo-controlled trials that will evaluate many doses of VX-548 in patients with acute pain subsequent bunionectomy operation or abdominoplasty surgical procedures. Equally reports will also include things like a hydrocodone bitartrate /acetaminophen reference arm. The primary endpoint in the two scientific tests is the time-weighted Sum of the Suffering Depth Change around the very first 48 hrs of cure (SPID48).

About VX-548

VX-548 is an oral, selective NaV1.8 inhibitor that has done Phase 1 studies in healthy volunteers. Dependent on a favorable pharmacokinetic, safety and tolerability profile, it was sophisticated to Stage 2 research in 2021.

NaV1.8 is a voltage-gated sodium channel that performs a significant function in suffering signaling in the peripheral anxious method. NaV1.8 is a genetically validated novel focus on for the cure of ache, and Vertex has beforehand shown scientific evidence-of-strategy with a little molecule investigational treatment focusing on NaV1.8 in several pain indications which includes acute discomfort, neuropathic suffering and musculoskeletal soreness.

Vertex’s approach is to selectively inhibit NaV1.8 applying smaller molecules with the goal of building a new class of medications that have the likely to offer outstanding reduction of acute soreness without having the limits of opioids, including their addictive possible. VX-548 is the most new molecule to enter clinical enhancement from Vertex’s portfolio of NaV1.8 inhibitors.

About Vertex

Vertex is a international biotechnology business that invests in scientific innovation to develop transformative medications for men and women with serious ailments. The enterprise has numerous permitted medicines that deal with the fundamental lead to of cystic fibrosis (CF) — a scarce, lifetime-threatening genetic disorder — and has various ongoing clinical and research systems in CF. Outside of CF, Vertex has a robust pipeline of investigational little molecule medicines in other critical illnesses the place it has deep perception into causal human biology, which include suffering, alpha-1 antitrypsin deficiency and APOL1-mediated kidney disorders. In addition, Vertex has a quickly growing pipeline of cell and genetic therapies for health conditions these types of as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetic issues mellitus.

Launched in 1989 in Cambridge, Mass., Vertex’s international headquarters is now positioned in Boston’s Innovation District and its intercontinental headquarters is in London. Additionally, the company has exploration and growth web-sites and business offices in North The usa, Europe, Australia and Latin The us. Vertex is consistently recognized as a person of the industry’s best locations to function, including 11 consecutive years on Science magazine’s Top rated Employers record and a very best spot to perform for LGBTQ equality by the Human Legal rights Campaign. For business updates and to learn much more about Vertex’s history of innovation, stop by www.vrtx.com or stick to us on Fb, Twitter, LinkedIn, YouTube and Instagram.

Special Note Pertaining to Forward-Wanting Statements

This press launch incorporates ahead-hunting statements as defined in the Personal Securities Litigation Reform Act of 1995, as amended, together with, without the need of limitation, statements by Dr. Carmen Bozic in this press release, and statements pertaining to our programs to begin a Section 2 review evaluating VX-548 in acute pain next abdominoplasty surgical treatment, the prospective benefits of VX-548 as a therapy for acute pain, and our ideas, expectations and anticipated timelines for these Stage 2 medical experiments, like our anticipations for obtainable facts. Even though Vertex thinks the forward-hunting statements contained in this push release are accurate, these forward-looking statements signify the company’s beliefs only as of the day of this push release and there are a number of hazards and uncertainties that could induce true activities or results to differ materially from individuals expressed or implied by these ahead-hunting statements. Individuals dangers and uncertainties involve, among other issues, that data from a restricted number of patients may not be indicative of last scientific demo final results, that possibly or the two of the research might not be done in the anticipated timeframe, or at all, that information from the company’s enhancement packages could not aid registration or more enhancement of its compounds thanks to security, efficacy, or other reasons, and other pitfalls shown beneath the heading “Risk Elements” in Vertex’s most latest annual report and subsequent filings submitted with the Securities and Trade Commission at www.sec.gov and out there by the company’s web site at www.vrtx.com. You really should not position undue reliance on these statements. Vertex disclaims any obligation to update the facts contained in this push release as new info results in being accessible.

(VRTX-GEN)

Look at resource model on businesswire.com: https://www.businesswire.com/news/house/20210719005192/en/

Contacts

Vertex Prescribed drugs Included
Traders:
Michael Partridge, +1 617-341-6108
or
Brenda Eustace, +1 617-341-6187
or
Manisha Pai, +1 617-429-6891

Media:
mediainfo@vrtx.com
or
U.S.: +1 617-341-6992
or
Heather Nichols: +1 617-839-3607
or
Intercontinental: +44 20 3204 5275